AI Neuromonitoring Expansion Will Drive Long-Term Opportunity In Acute And Pediatric Care

Catalysts

About CeriBell

CeriBell provides rapid, AI enabled point of care EEG solutions to improve seizure detection and neurological monitoring in acute care settings.

What are the underlying business or industry changes driving this perspective?

• Rapid expansion from roughly 10% penetration of U.S. acute care hospitals, coupled with an estimated 3% penetration of the core seizure detection market, leaves a long runway for new account additions that can support ongoing top line growth as the installed base scales revenue.
• Ongoing shift within hospitals to formal, guideline based seizure management protocols for stroke, cardiac arrest and hemorrhagic patients is driving broader, mandated EEG use, supporting higher utilization per account and an increasing mix of high margin recurring revenue.
• Regulatory and commercial progress in pediatric and neonatal indications, including 510(k) clearances and pilots in more than 200 NICUs, is expected to unlock a significant incremental opportunity and support same store growth and improved unit economics as fixed costs are leveraged.
• Development of additional AI algorithms for conditions such as delirium and stroke on top of a growing installed base transforms the platform from a single indication tool into a multi indication neuromonitoring system, potentially expanding the addressable market and supporting durable revenue diversification.
• Supply chain diversification with a new manufacturing line in Vietnam and a mid range target for higher gross margins, alongside disciplined OpEx growth and no current stated need for external capital, is intended to enhance resilience of net margins and support progress toward cash flow breakeven.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming CeriBell's revenue will grow by 28.8% annually over the next 3 years.
• Analysts are not forecasting that CeriBell will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate CeriBell's profit margin will increase from -63.3% to the average US Medical Equipment industry of 12.9% in 3 years.
• If CeriBell's profit margin were to converge on the industry average, you could expect earnings to reach $22.9 million (and earnings per share of $0.56) by about December 2028, up from $-52.5 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 60.6x on those 2028 earnings, up from -14.8x today. This future PE is greater than the current PE for the US Medical Equipment industry at 30.4x.
• Analysts expect the number of shares outstanding to grow by 3.42% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.72%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The company is still operating at a substantial net loss with operating expenses growing faster than revenue. If expected operating leverage does not materialize as growth investments continue, the path to cash flow breakeven could extend significantly, pressuring earnings and potentially necessitating dilutive capital raises despite current management intentions.
• Long term reliance on policy, reimbursement and guideline tailwinds to embed point of care EEG as standard of care could slow if hospitals deprioritize protocol updates or face budget constraints. This would delay deeper penetration within existing accounts and soften recurring revenue growth.
• Intensifying competition from other rapid EEG or neuromonitoring solutions and uncertainty around the timing and outcome of ongoing IP litigation could erode CeriBell's pricing power and win rates with large systems and the VA. This could negatively impact revenue growth and gross margins over time.
• The growth strategy depends heavily on successful commercialization of new indications such as pediatric, neonatal, delirium and stroke. Any delay in regulatory clearance, weaker than expected clinical uptake or unforeseen technical challenges could limit the anticipated expansion of the addressable market and reduce long term revenue and earnings potential.
• Exposure to geopolitical and trade risks in the supply chain, including tariffs on China sourced inventory and the need to ramp Vietnamese manufacturing, could keep gross margins at the low end of management expectations or lower if cost savings do not fully offset tariff headwinds. This would constrain future net margin improvement.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $27.0 for CeriBell based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $17.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be $177.0 million, earnings will come to $22.9 million, and it would be trading on a PE ratio of 60.6x, assuming you use a discount rate of 7.7%.
  
• Given the current share price of $20.93, the analyst price target of $27.0 is 22.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.